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ABSTRACT: The α4/6βδ-containing GABAA receptors are involved in a
number of brain diseases. Despite the potential of a δ-selective imaging
agent, no PET radioligand is currently available for in vivo imaging.
Here, we report the characterization of DS2OMe (1) as a candidate
radiotracer, 11C-labeling, and subsequent evaluation of [11C]DS2OMe in
a domestic pig as a PET radioligand for visualization of the δ-containing
GABAA receptors.
■ INTRODUCTION
γ-Aminobutyric acid (GABA) is the main inhibitory neuro-
transmitter in the central nervous system and exerts its major
physiological eﬀect via interaction with ionotropic GABAA
receptors (GABAARs). The GABAARs are assembled from a
variety of subunits (α1−6, β1−3, γ1−3, δ, ε, θ, π, and ρ1−3)
forming hetero- or homopentameric complexes in various
combinations.1,2 The subunit composition of GABAARs
appears to diﬀer with subcellular localization, which dictates
the type of inhibition mediated.3 The majority of GABAARs
has the general stoichiometry of 2α, 2β, and 1γ subunits.4
However, in a subpopulation of receptors, the δ-subunit
replaces the γ-subunit. δ-subunit-containing GABAARs, for
example, α4βδ, α6βδ, and α1β2δ, are primarily found in peri- or
extrasynaptic locations where they mediate tonic inhibition,
distinct from the fast and transient synaptic inhibition.5,6
Aberrant tonic inhibition mediated by α4/6βδ-containing
receptors has been implicated under various pathophysio-
logical conditions and related to discrete brain regions,1
including stroke (cortex),7 Angelman syndrome (cerebellum),8
sleep-related disorders (thalamus),9 and depression (hippo-
campus).10 Therefore, these receptors have received a great
deal of attention in the last decades as potential drug targets.11
Consequently, development of selective tool compounds and
diagnostics to further understand the pharmacology and
physiological roles of these receptors will prove therapeutically
important.
Among the orthosteric ligands reported, the functional δ-
preferring orthosteric agonist THIP (gaboxadol) (Figure 1)
has been pursued as a novel treatment for insomnia, reaching
phase III clinical development. Gaboxadol is at present in
phase III clinical trials for treatment of Angelman syndrome.12
The imidazopyridine DS2, a functionally selective α4/6β3δ
positive allosteric modulator (PAM), relative to its action at
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α4β3γ2 and α1β3γ2 receptors, has been reported.
13,14 However,
poor brain penetration precludes the use of DS2 for in vivo
studies.15
Recently, we reported a structure−activity study on the δ-
selective imidazopyridine DS2 (Figure 1) and the correspond-
ing 6,8-dibromo analogue DS1 and the direct modulatory
eﬀect on [3H]-ethynylbicycloorthobenzoate ([3H]-EBOB)
binding to δ-containing GABAARs.
16 EBOB is a potent
noncompetitive GABAAR antagonist that binds to the
picrotoxinin-binding site within the GABAAR ion channel.
[3H]-EBOB binding is sensitive to conformational changes in
the chloride channel, which can be mediated by increasing
concentrations of GABA and/or are aﬀected by modulators in
the presence or absence of GABA.17−20
Since the δ-containing GABAARs are potentially involved in
the pathogenesis and symptoms of several disorders in the
central nervous system, a positron emission tomography
(PET) tracer would be a valuable tool. Inspired by the
structure−activity study mentioned above, we herein report
the identiﬁcation, radiosynthesis, and in vivo PET studies of a
low micromolar potency, selective, and brain-penetrant PAM
of δ-containing GABAARs ([
11C]DS2OMe, [11C]1), in pig, as
a promising lead candidate for imaging the δ-containing
GABAARs.
■ RESULTS AND DISCUSSION
Initially, a potential 11C-labelling site in the core scaﬀold of
DS2 was identiﬁed based on the reported structure−activity
study and the experience obtained on the chemistry involved.16
Since the p-hydroxy analogue 2 (see Scheme 1) appears as an
attractive precursor amenable for radiolabeling via conven-
tional 11C-methylation, the [11C]-p-methoxy analogue of DS2
([11C]1) was selected as the candidate radiotracer.
To probe the applicability of [11C]1 as a speciﬁc radiotracer
for the δ-containing GABAARs, the selectivity proﬁles of 1 and
DS2 as PAMs were compared using a ﬂuorescence-based
FLIPR membrane potential (FMP) assay, based on the
transient expression of human α1/4/6 and β2 subunits in a
HEK293 Flp-In cell line, stably expressing the human δ-
subunit,21 or γ2 instead of δ for comparison. To this end, the
concentration of GABA corresponding to GABA EC20 was ﬁrst
determined from the full concentration−response curves of
GABA for each of the tested receptors (Table 1). Then, 1 and
DS2 were tested as PAMs in the presence of the determined
EC20 GABA concentration. To investigate the importance of
the α-subunit for PAM activity, the subtypes, α1β2δ, α4β2δ, and
α6β2δ, were compared. Full concentration−response curves
showed that 1 and DS2 displayed near equipotent PAM
activities (1−4 μM) at the diﬀerent α-subunit-containing
receptors (Table 1, Figure 2). In parallel, to conﬁrm δ-subunit
selectivity, 1 was also tested as a PAM at α6β2γ2s. As shown,
neither DS2 nor 1 had any eﬀect at this non-δ-containing
receptor subtype when tested at concentrations up to 10 μM
(Table 1, Figure 2). These data summarizes 1 as a novel δ-
selective DS2-analogue with low micromolar PAM activity.
The cell line stably expressing the δ-subunit has previously
been used to study DS2 at α4β1δ versus binary α4β1/3 receptors
using both the FMP assay and whole-cell patch-clamp
recordings, conﬁrming that DS2 is δ-selective.16
The selectivity was further explored in The National
Institute of Mental Health’s Psychoactive Drug Screening
Program (NIMH-PDSP) (Supporting Information Table S1),
where binding aﬃnity and cross selectivity of 1 to a large panel
of brain targets was assessed. 1 did not show signiﬁcant aﬃnity
(Ki > 10 μM) for other tested biogenic receptors and
transporters (45 in total).
The high selectivity for δ-containing GABAARs establish 1 as
an interesting compound, as a PET radiotracer candidate, for
further studying the δ-containing GABAARs. Furthermore,
since O-demethylation in general is a major metabolic pathway,
the O-demethylated compound may be the major metabolite
for 1. Therefore, radiolabeling of the methoxy group, resulting
in [11C]1 via radiomethylation of the hydroxyl analogue (2),
was rendered the most suitable strategy to avoid/limit
radioactive metabolite formation.
Consequently, radiosynthesis of 1 was probed to obtain the
corresponding [11C]1. To obtain the hydroxylated precursor,
2, a three-step procedure was applied, as previously reported,16
using 2-aminopyridine, thiophen-2-carbaldehyde, and potas-
sium cyanide in a multicomponent reaction, followed by
amide-bond formation using 4-acetoxybenzoyl chloride. The
removal of the acetoxy group was accomplished with 5 M
NaOH in tetrahydrofuran at room temperature.
The nonradiolabeling experiment was performed by using
methyl triﬂate and 2 M NaOH in acetone for 3 min at 80 °C to
enable the introduction of O-methyl into 2 aﬀording the target
compound 1.
The radiosynthesis of [11C]DS2OMe ([11C]1) was
performed in a fully automated system. [11C]CH3OTf was
dissolved in acetone containing the precursor and base and
reacted for 5 min at 60 °C. Isolation of the ﬁnal radiotracer, see
Scheme 1, could be achieved via semipreparative high-
performanec liquid chromatography (HPLC) with a total
synthesis time of 37 min (Supporting Information Figures S1
and S2).
The radiolabeled compound [11C]1 was produced with a
good radiochemical yield of 19.9 ± 1.2% (n = 3, decay
corrected), suﬃcient chemical and radiochemical purity of
>95%, and very high molar activities of 188−215 GBq/μmol.
Using the radiochemistry described and delineated in
Scheme 1, [11C]1 was prepared for evaluation in in vivo
PET imaging studies in a domestic pig using a high-resolution
research tomography (HRRT) PET scanner. As an exper-
Figure 1. Chemical structures of GABA, the orthosteric agonist
THIP/gaboxadol, and the two PAMs, DS2 and DS2OMe (1).
Scheme 1. Synthesis of [11C]1
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imental animal, the pig allows us to acquire the arterial input
function necessary for kinetic modelling of the data. The pig
also has a larger and gyrenchephalic brain giving it a higher
translational value compared to, for example, rats. [11C]1
successfully entered the pig brain, with the radioligand uptake
being fairly uniform across diﬀerent brain regions (Figure 3A).
From the time−activity curves, it is also evident that [11C]1
has fast tracer kinetics in the four diﬀerent regions measured,
meaning that the retention of the tracer in the brain is limited
(Figure 3B). Two other baseline PET experiments were
conducted in two other pigs, showing a similar uniform uptake
and fast tracer kinetics (data not shown).
In one pig, we performed ﬁrst the baseline scan and
subsequently a self-block experiment, where we coinjected 2.1
mg/kg nonlabeled 1 along with [11C]1 (Figure 3C). Kinetic
modelling of the baseline and self-block PET data conﬁrmed
that the binding of [11C]1 is quite uniform across the brain.
The total distribution volume (VT) in the baseline situation
was the highest in the cortex (5.6 mL/cm3), followed by the
striatum (4.5 mL/cm3), thalamus (3.8 mL/cm3), hippocampus
(3.8 mL/cm3), and last cerebellum (3.4 mL/cm3). This is not
in accordance with the reported distribution of α4/6δ
containing GABAARs. After administration of unlabeled 1,
VTs was decreased in all regions: VT decreased by ∼40% in the
hippocampus and cortex, whereas VT decreased by ∼18% in
the thalamus and cerebellum (Supporting Information Figure
S3A) indicating that there is some speciﬁc binding of [11C]1.
Radiometabolite analysis of plasma samples from the pig
revealed that the metabolism of [11C]1 was fast with only 50%
of the parent compound remaining after ∼5 min. If the
metabolism of 1 is similarly fast in pharmacological doses, it
would render this compound unsuited as a clinical drug. It is
possible that the fast metabolism of [11C]1 is the reason for the
observed fast tracer kinetics. After self-blockade, the radio-
metabolism of [11C]1 was similar to the baseline situation
(Supporting Information Figure S3B). Only early eluting
radiometabolites were detected with our radio-HPLC method,
suggesting that these metabolites were of a polar nature
(Supporting Information Figure S4). The free fraction of [11C]
1 in pig plasma was measured to 15% using a dialysis chamber
method with an incubation time of 3 h. This is comparable to
other radiotracers evaluated in pigs.22,23
In conclusion, we here show a high uptake of [11C]1 into the
pig brain but the uptake is uniform and clears quickly.
However, when the uptake was quantiﬁed, we found decreases
in binding after self-blockade, indicating some speciﬁc binding.
In contrast to DS2,13 [11C]1 enters the brain, which, together
with its selectivity for δ-containing GABAARs, renders 1 a
promising lead in developing a radiotracer for the target.
Table 1. Obtained PAM EC50 Values for 1 and DS2 at Selected GABAA Receptor Subtypes
a
EC50 (μM) (pEC50 0ESEM, n) EC20 (μM)
1b DS2b GABA GABA
α1β2δ 3.68 (5.43 ± 0.055, 4) 2.97 (5.53 ± 0.13, 3) 6.71 (5.17 ± 0.087, 4) 1.6−2.0
α4β2δ 2.91 (5.54 ± 0.069, 3) 1.41 (5.85 ± 0.085, 3) 0.25 (6.61 ± 0.030, 3) 0.08
α6β2δ 2.25 (5.65 ± 0.0038, 3) 2.02 (5.69 ± 0.10, 3) 0.21 (6.68 ± 0.13, 3) 0.05
α6β2γ2s no modulation (n = 3) no modulation (n = 3) 0.50 (6.30 ± 0.091, 3) 0.1−0.2
aGABA agonist EC50 values are given for reference and GABA EC20 used for PAM testing is also given. No modulation means no activity at 10 μM.
bTested as PAMs in the presence of the stated GABA EC20.
Figure 2. Concentration−response curves of the modulation of
GABA EC20 by 1 at α6β2δ and α6β2γ2s receptors and DS2 at α6β2δ
receptors, tested in the FMP assay. Data are shown as mean reSD of a
single representative experiment performed with three technical
triplicates. Two additional experiments gave similar results; data are
summarized in Table 1.
Figure 3. (A) PET images of the pig brain in the transverse, sagittal,
and coronal planes (left to right). (B) Time−activity curves of [11C]1
in the indicated regions of the pig brain. (C) Time−activity curves of
[11C]1 in the thalamus and cerebellum at the baseline (closed
symbols) and after administration of 2.1 mg/kg unlabeled 1
(coadministrated with the tracer, open symbols). SUV: standardized
uptake value. Tha: thalamus, Str: striatum, Ctx: cortex, Cb:
cerebellum.
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■ EXPERIMENTAL SECTION
Radiosynthesis of [11C]DS2OMe ([11C]1). [11C]methyl
triﬂuoromethanesulfonate ([11C]MeOTf) was produced in an
automated system and trapped in 300 μL of acetone solution
containing the precursor 4-hydroxy-N-(2-(thiophen-2-yl)-
imidazo[1,2-a]pyridin-3-yl)benzamide (2, 0.1 mg, 0.3 μmol)
and 5 μL 2 N NaOH at room temperature. The reaction
mixture was heated for 5 min at 60 °C before it was diluted in
4.3 mL 0.1% phosphoric acid and isolated using semi-
preparative HPLC [C18 Onyx Semiprep monolithic column
(Phenomenex Inc. 100 × 10 mm), 70:30 100 mM phosphate-
buﬀer/EtOH, at a ﬂow rate of 6 mL/min]. Retention times
were 400 s for [11C]1 and 200−225 s for 2 (see Supporting
Information Figure S1). The labeled product was collected
into a sterile 20 mL vial containing phosphate-buﬀer (9 mL,
100 mM, pH 7). The ﬁnal product was analyzed by analytical
HPLC [Luna, 5μ, C-18(2) 100 Å column (Phenomenex Inc.
150 4.6 mm); 60:40 0.01 M sodium borate buﬀer/acetonitrile;
1.5 mL/min]. Retention time for 1 was 4.48 min (see
Supporting Information Figure S2). The overall synthesis,
puriﬁcation, and formulation time was approximately 40 min.
The product [11C]1 could be produced and isolated with
suﬃcient molar activities (188−215 GBq/μmol (n = 2)) and
radiochemical purities above 95%.
FMP Blue Assay on GABAA Receptors Expressed in
HEK-293 Cells. The FMP assay was performed on HEK-293
Flp-In cells expressing human recombinant GABAA receptors
using conditions for cell-culturing and transfection as described
previously.21 In brief, the cells were plated for transfection 24 h
later with GABAA receptor plasmids with the Polyfect
Transfection Reagent (Qiagen, West Sussex, UK). For
expression of the δ-containing GABAA receptor subtypes,
α1β2δ, α4β2δ, and α6β2δ, HEK-293 Flp-In cells stably
expressing the GABAA δ-subunit were transfected by a 1:1
ratio of either α1, α4 (both pUNIV) (Addgene, Cambridge,
MA, USA),24 or α6 (pcDNA3.1zeo) and β2 (pcDNA3.1zeo).
25
α6β2γ2s receptors were transiently expressed in background
HEK-293 Flp-In cells21 using a 1:1:2 ratio of α6-, β2- and γ2s-
subunits, respectively.
Transfected cells 16−24 h post-transfection were plated into
poly-D-lysine coated black clear bottom 96-well plates (BD
Biosciences, Bedford, MA, USA) at a density of 50 000 cells/
well and incubated for 16−20 h. On the day of the assay, the
medium was aspirated, and the cells were washed in 100 μL/
well assay buﬀer [HBSS (Life technologies, Paisley, UK) + 20
mM HEPES pH 7.4] followed by addition of 100 μL/well of
the FMP blue dye (0.5 mg/mL) (Molecular Devices,
Sunnyvale, CA, USA) and incubated in the dark for 30 min
in a CO2 incubator at 37 °C and 5% CO2. Ligand solutions
were prepared in 5× in assay buﬀer, which for testing of the
PAMs contained a concentration of GABA corresponding to
GABA EC20. The GABA EC20 concentrations were determined
from full GABA concentration−response curves for each
subtype, as described in the Results and Discussion section.
Before reading of the plate, the ligand solutions were added to
96-well ligand plates and incubated for 15 min at 37 °C in the
NOVOstar plate reader (BMG, LABTECH GmbH, Oﬀenburg,
Germany). Fluorescence was determined by excitation of the
dye at 530 nm and emission at 560 nm. The relative changes in
the ﬂuorescent signal (ΔFU) were analyzed by subtracting the
baseline signal from the maximum peak/plateau signal induced
by the ligands. Fluorescence signals were visually inspected,
and any artefacts were manually omitted from the analysis.
Concentration−response curves were ﬁtted to obtain EC50
values using the four-parameter concentration−response curve
using GraphPad Prism 7.0 (GraphPad Software Inc., San
Diego, CA, USA)
Response bottom
top bottom
1 10 n((log(EC ) A ) )50 H
= + −
+ −[ ] ·
with bottom and top being the lower (e.g., the GABA EC20
level) and upper plateau responses, respectively. [A]
corresponds to the logarithmic concentration of the ligand
and nH to the hill slope of the curve. The obtained EC50 values
are based on at least three independent experiments with each
data point performed with technical triplicates.
Animal Procedures, Pigs. One female domestic pig
(crossbreed of Landrace × Yorkshire × Duroc, 22 kg) was used
for in vivo PET imaging. All animal procedures were approved
by the Danish Council for Animal Ethics (journal no. 2012-15-
2934-00156). [11C]1 was given as intravenous (iv) bolus, and
the injected dose was 509 MBq in the baseline scan and 488
MBq in the self-block scan. Molar activity at the time of
injection was 129 and 113 GBq/μmol resulting in an injected
mass of 1.37 and 1.51 μg. The pig was scanned twice for 90
min in the list mode. For the second (self-block) scan, [11C]1
was coinjected with 2.14 mg/kg unlabelled 1. 1 was dissolved
in 10% beta-cyclodextrin solution (Sigma-Aldrich).
The animal was housed under standard conditions and was
allowed to acclimatize for 1 week. Before scanning, anaesthesia
was induced with im injection of 0.13 mL/kg Zoletil veterinary
mixture (10.87 mg/kg xylazine + 10.87 mg/kg ketamine + 1.74
mg/kg methadone + 1.74 mg/kg butorphanol + 10.87 mg/kg
tiletamine + 10.87 mg/kg zolezepam). Thereafter, anaesthesia
was maintained with constant propofol infusion [1.5 mg/kg/h
intravenous (iv); B. Braun, Melsungen, Germany]. Arterial iv
access for drawing blood was granted in the right femoral
artery via a minor incision, and two venous iv lines for
injections were granted in the left and right mammary veins.
Analgesia was assured by iv injection of fentanyl during
surgery. During anaesthesia, animals were endotracheally
intubated and ventilated. Vital parameters (heart rate, body
temperature, blood pressure, blood glucose, oxygen saturation,
and end tidal CO2) were continuously monitored during the
scan.
Blood Sampling. During the ﬁrst 30 min of the scans,
radioactivity in the whole blood was continuously measured
using an ABSS autosampler (Allogg Technology, Mariefred,
Sweden) counting coincidences in a lead-shielded detector.
Concurrently, arterial whole blood was sampled manually at
times 2.5, 5, 10, 20, 30, 40, 50, 70, and 90 min after injection of
[11C]1. Total radioactivity in plasma (500 μL) and whole
blood (500 μL) was measured in a well counter (Cobra 5003;
Packard Instruments, Meriden, CT, USA), which was cross-
calibrated to the HRRT scanner and autosampler. All
measurements of radioactivity were decay-corrected to the
time of radioligand injection.
The free fraction of [11C]1 in pig plasma was measured
using an equilibrium dialysis method as previously described26
and calculated as the ratio between radioactivity in a buﬀer and
plasma.
Metabolite analysis. Radiolabelled parent compound and
metabolites were determined by direct injection of plasma into
a radio-HPLC system (Dionex Ultimate 3000; Thermo Fisher
Scientiﬁc, Hvidovre, Denmark) conﬁgured for column switch-
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ing. Manually drawn arterial whole blood samples were
centrifuged (1500g, 7 min, 4 °C), and plasma was ﬁltered
through a syringe ﬁlter (Whatman GD/X 13 mm or 25 mm,
poly(vinylidene diﬂuoride) membrane, 0.45 μm pore size;
Frisenette ApS, Knebel, Denmark) before the analysis by
HPLC as previously described.27
Reconstruction and quantiﬁcation of PET data.
Ninety-minute list-mode PET data were reconstructed in 38
dynamic frames (6 × 10, 6 × 20, 4 × 30, 9 × 60, 2 × 180, 8 ×
300, and 3 × 600 s). Images consisted of 207 planes of 256 ×
256 voxels of 1.22 × 1.22 × 1.22 mm. A summed picture of all
counts in the 90 min scan was reconstructed for the pig and
used for coregistration to a multimodal pig brain atlas, as
described by Villadsen et all.28 The time−activity curves were
calculated for the following volumes of interest (VOIs): cortex,
hippocampus, thalamus, striatum, and cerebellum (excluding
the vermis). Outcome measure in the time−activity curves was
calculated as the radioactive concentration in the VOI (in
kBq/mL) normalized to the injected dose corrected for animal
weight (in kBq/kg), yielding standardized uptake values (g/
mL). Quantiﬁcation of the binding was performed in PMOD
(version 3.0) with the Logan graphical analysis, using the
metabolite-corrected arterial plasma concentration to calculate
the total distribution volume (VT).
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